Product news

Share this content:
The FDA warned healthcare professionals about six cases of hemorrhagic or necrotizing pancreatitis in patients taking Byetta (exenatide), indicated for Type 2 diabetes. Amylin and Eli Lilly & Co., joint manufacturers of Byetta, will make labeling changes featuring more prominent warnings about the risk of acute hemorrhagic or necrotizing pancreatitis.
Share this content:
Scroll down to see the next article